This paper explores how changes in genetics, database, high-throughput screening and bioinformatics technologies have allowed pharmaceutical firms to exploit economies of scale in experimentation. Traditional craft-based, sequential experimentation in chemistry and biology has been complemented by firstly, the automated, mass-production analysis of populations and secondly, by "in silico" experimentation using simulations and databases. The changes are analysed within a Chandlerian framework that highlights how increases in the "throughput" of R&D are dependent on organizational and managerial responses to systemic uncertainty. Copyright 2000 by Oxford University Press.
Download Info
To our knowledge, this item is not available for
download. To find whether it is available, there are three
options:
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page
whether it is in fact available.
3. Perform a search for a similarly titled item that would be
available.
Contact details of provider: Postal: Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK Fax: 01865 267 985 Email: Web page: http://icc.oupjournals.org/
For technical questions regarding this item, or to correct its listing, contact: (Christopher F. Baum).
Related research
Keywords:
Cited by: (explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)